#MedNews: Pennsylvania has reported more than 1300 measles cases, the highest number in a single state since 1991.
With outbreaks growing across the US amid declining vaccine coverage, could this become the new normal?
With outbreaks growing across the US amid declining vaccine coverage, could this become the new normal?
Pennsylvania Tops 1000 Measles Cases
This Medical News article discusses ongoing measles outbreaks in Pennsylvania and other US states amid declining vaccine coverage.
jamanetwork.com
October 30, 2026 at 3:58 PM
#MedNews: Pennsylvania has reported more than 1300 measles cases, the highest number in a single state since 1991.
With outbreaks growing across the US amid declining vaccine coverage, could this become the new normal?
With outbreaks growing across the US amid declining vaccine coverage, could this become the new normal?
#MedNews: As the use of #GLP-1 drugs expands, questions remain about how the medications affect people with frailty. Here's what a recent study found.
Are GLP-1 Drugs Safe in Frailty?
This Medical News article discusses an analysis of cardiovascular benefits and safety of semaglutide use in trial participants with frailty, defined by accumulated age-related health deficits.
jamanetwork.com
October 30, 2026 at 3:58 PM
From #ESMO2026 - Among people with previously treated, CLDN18.2-positive, advanced gastroesophageal cancer, treatment with sonesitatug vedotin significantly extends overall survival.
Full story 👉️ buff.ly/gHWj4e6
#MedNews #OncSky
Full story 👉️ buff.ly/gHWj4e6
#MedNews #OncSky
CLARITY-Gastric01 supports Sone-Ve for pretreated CLDN18.2-positive gastroesophageal cancer
Among people with previously treated, CLDN18.2-positive, advanced gastroesophageal cancer, treatment with sonesitatug vedotin significantly extends overall survival.
www.springermedicine.com
November 2, 2026 at 7:25 PM
From #ESMO2026 - Among people with previously treated, CLDN18.2-positive, advanced gastroesophageal cancer, treatment with sonesitatug vedotin significantly extends overall survival.
Full story 👉️ buff.ly/gHWj4e6
#MedNews #OncSky
Full story 👉️ buff.ly/gHWj4e6
#MedNews #OncSky
From #ESMO2026 - Patients with stage IIB–IV cutaneous melanoma derive a significant recurrence-free survival benefit from adding a personalized mRNA-based #CancerVaccine to adjuvant pembrolizumab.
Full story 👉️ buff.ly/SNRpApq
#MedNews
Full story 👉️ buff.ly/SNRpApq
#MedNews
Adjuvant treatment with mRNA melanoma vaccine reduces recurrence risk
Patients with stage IIB–IV cutaneous melanoma derive a significant recurrence-free survival benefit from adding a personalized mRNA-based cancer vaccine to adjuvant pembrolizumab.
www.springermedicine.com
November 2, 2026 at 4:15 PM
From #ESMO2026 - Patients with stage IIB–IV cutaneous melanoma derive a significant recurrence-free survival benefit from adding a personalized mRNA-based #CancerVaccine to adjuvant pembrolizumab.
Full story 👉️ buff.ly/SNRpApq
#MedNews
Full story 👉️ buff.ly/SNRpApq
#MedNews
More than a quarter of Americans have exaggerated or invented symptoms to get antibiotics, a new JAMA Network Open study found. Most cited cold-like symptoms. But antibiotics do not treat viruses like the flu and COVID, and overuse fuels resistance. www.drugs.com/news/more-th...
More Than A Quarter Of Americans Fib To Get Antibiotics, Study Finds - Drugs.com MedNews
MONDAY, Nov. 2, 2026 More than a quarter of Americans have exaggerated or invented symptoms to try to get antibiotics from their doctor, a new study says.The ma
www.drugs.com
November 2, 2026 at 6:19 PM
More than a quarter of Americans have exaggerated or invented symptoms to get antibiotics, a new JAMA Network Open study found. Most cited cold-like symptoms. But antibiotics do not treat viruses like the flu and COVID, and overuse fuels resistance. www.drugs.com/news/more-th...
A new study suggests high-dose omega-3 may help some advanced colon cancer patients live longer. About 62% of patients taking 4 grams of EPA daily survived five years, versus 45% on placebo. The findings are preliminary until published and peer-reviewed. www.drugs.com/news/omega-3...
Omega-3s Might Improve Survival In Advanced Cancer, Trial Finds - Drugs.com MedNews
FRIDAY, Oct. 30, 2026 High-dose omega-3 fatty acid supplements might improve survival among some patients with advanced colon cancer, a new study says. Patients
www.drugs.com
October 30, 2026 at 5:50 PM
A new study suggests high-dose omega-3 may help some advanced colon cancer patients live longer. About 62% of patients taking 4 grams of EPA daily survived five years, versus 45% on placebo. The findings are preliminary until published and peer-reviewed. www.drugs.com/news/omega-3...
A draft HHS policy would let compounding pharmacies sell six unapproved peptide injections, including BPC-157 and TB-500. None have passed FDA review for safety. The Associated Press reports FDA scientists largely oppose it. Public comment is open for two weeks. www.drugs.com/news/unprove...
Unproven Peptides Opposed By FDA Scientists Could Soon Be Easier To Get - Drugs.com MedNews
THURSDAY, Oct. 29, 2026 Six unapproved peptide injections popular in the wellness world could soon be sold by compounding pharmacies, under a draft federal poli
www.drugs.com
October 29, 2026 at 6:02 PM
A draft HHS policy would let compounding pharmacies sell six unapproved peptide injections, including BPC-157 and TB-500. None have passed FDA review for safety. The Associated Press reports FDA scientists largely oppose it. Public comment is open for two weeks. www.drugs.com/news/unprove...
A personalized vaccine plus immunotherapy cut the risk of recurrence or death by 42% in advanced melanoma patients, a phase 3 trial presented at ESMO found. Findings are preliminary until peer-reviewed. Longer follow-up is needed to confirm the survival benefits. www.drugs.com/news/cancer-...
Cancer Vaccine Could Boost Melanoma Survival, Trial Finds - Drugs.com MedNews
WEDNESDAY, Oct. 28, 2026 A personalized cancer vaccine can significantly improve survival odds for patients with advanced melanoma, a new clinical trial has fou
www.drugs.com
October 28, 2026 at 5:46 PM
A personalized vaccine plus immunotherapy cut the risk of recurrence or death by 42% in advanced melanoma patients, a phase 3 trial presented at ESMO found. Findings are preliminary until peer-reviewed. Longer follow-up is needed to confirm the survival benefits. www.drugs.com/news/cancer-...
New ACOG guidance on menopause emphasizes individualized hormone therapy. Healthy women generally benefit most when starting before age 60 or within 10 years of menopause. Guidelines also cover nonhormonal options and practical ways to protect bone and heart health. www.drugs.com/news/doctor-...
A Doctor’s Take On New Menopause Guidelines - Drugs.com MedNews
TUESDAY, Oct. 27, 2026 Many women I see in my practice have questions about menopause and hormone therapy. The newest guidelines from the American College of Ob
www.drugs.com
October 27, 2026 at 6:20 PM
New ACOG guidance on menopause emphasizes individualized hormone therapy. Healthy women generally benefit most when starting before age 60 or within 10 years of menopause. Guidelines also cover nonhormonal options and practical ways to protect bone and heart health. www.drugs.com/news/doctor-...
From #UEGWeek2026 - The synthetic corticosteroid budenoside may be an effective treatment for patients with refractory celiac disease type 1.
Full story 👉️ buff.ly/Tpb3Opk
#GISky #MedNews
Full story 👉️ buff.ly/Tpb3Opk
#GISky #MedNews
Budenoside reduces refractory symptoms in patients with celiac disease
The synthetic corticosteroid budenoside may be an effective treatment for patients with refractory celiac disease type 1.
www.springermedicine.com
October 24, 2026 at 3:15 PM
From #UEGWeek2026 - The synthetic corticosteroid budenoside may be an effective treatment for patients with refractory celiac disease type 1.
Full story 👉️ buff.ly/Tpb3Opk
#GISky #MedNews
Full story 👉️ buff.ly/Tpb3Opk
#GISky #MedNews
From #UEGWeek2026 - Primary percutaneous stenting may be a better option than endoscopic biliary drainage for managing unresectable malignant hilar biliary obstruction.
Full story 👉️ buff.ly/HrS8xea
#GISky#MedNews
Full story 👉️ buff.ly/HrS8xea
#GISky#MedNews
TESLA study backs primary percutaneous stenting for hilar biliary obstruction
Primary percutaneous stenting may be a better option than endoscopic biliary drainage for managing unresectable malignant hilar biliary obstruction.
www.springermedicine.com
October 25, 2026 at 7:25 PM
From #UEGWeek2026 - Primary percutaneous stenting may be a better option than endoscopic biliary drainage for managing unresectable malignant hilar biliary obstruction.
Full story 👉️ buff.ly/HrS8xea
#GISky#MedNews
Full story 👉️ buff.ly/HrS8xea
#GISky#MedNews
#MedNews: Affecting an estimated 1.7 billion people worldwide, steatotic liver disease is emerging as an international public health issue.
Read more:
Read more:
Steatotic Liver Disease: A Global Problem
This Medical News article discusses international efforts to determine the prevalence and increase awareness and detection of steatotic liver disease, which affects an estimated 1.7 billion people wor...
jamanetwork.com
October 23, 2026 at 4:49 PM
#MedNews: Affecting an estimated 1.7 billion people worldwide, steatotic liver disease is emerging as an international public health issue.
Read more:
Read more:
Starting survivorship care early may help cancer patients. In 471 head and neck cancer patients, those who began care before or during radiation had a 38% lower risk of recurrence and better treatment adherence, a new JAMA Otolaryngology study found. www.drugs.com/news/patient...
Patients With Cancer Live Longer, Healthier When They Start Survivorship Care Before Or During Treatment - Drugs.com MedNews
MONDAY, Oct. 26, 2026 Starting survivorship care for patients with cancer before or during treatment can help them live longer and avoid cancer recurrence, a ne
www.drugs.com
October 26, 2026 at 6:07 PM
Starting survivorship care early may help cancer patients. In 471 head and neck cancer patients, those who began care before or during radiation had a 38% lower risk of recurrence and better treatment adherence, a new JAMA Otolaryngology study found. www.drugs.com/news/patient...
#MedNews: #Testosterone use among women is rising, but does the evidence support it?
A recent US FDA workshop brought new attention to the push for a testosterone product designed specifically for women.
A recent US FDA workshop brought new attention to the push for a testosterone product designed specifically for women.
The Rise in Testosterone Therapy for Women
This Medical News article discusses growing use of testosterone therapy among women, and a US Food and Drug Administration public workshop that explored the current evidence on its use beyond sexual f...
jamanetwork.com
October 23, 2026 at 4:49 PM
#MedNews: #Testosterone use among women is rising, but does the evidence support it?
A recent US FDA workshop brought new attention to the push for a testosterone product designed specifically for women.
A recent US FDA workshop brought new attention to the push for a testosterone product designed specifically for women.
From #EASD2026 - Watch as Prof. Liana Billings describes phase 2 trial findings for #eloralintide alone or alongside tirzepatide in people with type 2 diabetes and obesity.
Full video 👉️ buff.ly/qfSqQVY
#MedNews
Full video 👉️ buff.ly/qfSqQVY
#MedNews
October 23, 2026 at 6:25 PM
From #EASD2026 - Watch as Prof. Liana Billings describes phase 2 trial findings for #eloralintide alone or alongside tirzepatide in people with type 2 diabetes and obesity.
Full video 👉️ buff.ly/qfSqQVY
#MedNews
Full video 👉️ buff.ly/qfSqQVY
#MedNews
From #UEGWeek2026 - Patients with moderately to severely active ulcerative colitis are significantly more likely to achieve clinical remission after 12 weeks of icotrokinra than placebo.
Full story 👉️ buff.ly/55h7HNB
#GISky #MedNews
Full story 👉️ buff.ly/55h7HNB
#GISky #MedNews
Oral IL-23 receptor inhibition approach feasible for moderately to severely active UC
Patients with moderately to severely active ulcerative colitis are significantly more likely to achieve clinical remission after 12 weeks of icotrokinra than placebo.
www.springermedicine.com
October 24, 2026 at 8:01 AM
From #UEGWeek2026 - Patients with moderately to severely active ulcerative colitis are significantly more likely to achieve clinical remission after 12 weeks of icotrokinra than placebo.
Full story 👉️ buff.ly/55h7HNB
#GISky #MedNews
Full story 👉️ buff.ly/55h7HNB
#GISky #MedNews
From #UEGWeek2026 - Children and adolescents with moderate-to-severe ulcerative colitis may derive long-term benefit from induction therapy with mirikizumab.
Full story 👉️ buff.ly/CFyP2Cs
#MedNews #GISky
Full story 👉️ buff.ly/CFyP2Cs
#MedNews #GISky
Mirikizumab pediatric UC trial results SHINE-2 at UEG Week 2026
Children and adolescents with moderate-to-severe ulcerative colitis may derive long-term benefit from induction therapy with mirikizumab.
www.springermedicine.com
October 23, 2026 at 3:15 PM
From #UEGWeek2026 - Children and adolescents with moderate-to-severe ulcerative colitis may derive long-term benefit from induction therapy with mirikizumab.
Full story 👉️ buff.ly/CFyP2Cs
#MedNews #GISky
Full story 👉️ buff.ly/CFyP2Cs
#MedNews #GISky
The FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B, the first drug of its kind. In two trials, 19% kept the virus in check six months after stopping all treatment. It carries a boxed warning for serious risks. www.drugs.com/news/fda-app...
FDA Approves Hepatitis B Shot That May Let Some Patients Stop All Treatment - Drugs.com MedNews
FRIDAY, Oct. 23, 2026 Some adults with chronic hepatitis B may now have a path to something today s treatments rarely deliver stopping all medication while the
www.drugs.com
October 23, 2026 at 5:35 PM
The FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B, the first drug of its kind. In two trials, 19% kept the virus in check six months after stopping all treatment. It carries a boxed warning for serious risks. www.drugs.com/news/fda-app...
From #UEGWeek2026 - Budenoside orodispersible tablets at a dose of 2 mg twice daily significantly reduce the formation of esophageal strictures in people with esophageal cancer undergoing endoscopic submucosal dissection.
👉️ buff.ly/C9Zr3pj
#MedNews
👉️ buff.ly/C9Zr3pj
#MedNews
Budenoside tablets protect against esophageal strictures after endoscopic submucosal dissection
Budenoside orodispersible tablets at a dose of 2 mg twice daily significantly reduce the formation of esophageal strictures in people with esophageal cancer undergoing endoscopic submucosal…
www.springermedicine.com
October 22, 2026 at 8:01 AM
From #UEGWeek2026 - Budenoside orodispersible tablets at a dose of 2 mg twice daily significantly reduce the formation of esophageal strictures in people with esophageal cancer undergoing endoscopic submucosal dissection.
👉️ buff.ly/C9Zr3pj
#MedNews
👉️ buff.ly/C9Zr3pj
#MedNews
In a study of 375 women aged 50 and older, about 1 in 4 developed a urinary tract infection after hip fracture surgery. Those who had used vaginal estrogen beforehand were more likely to, though most already had recurrent UTIs. www.drugs.com/news/after-h...
After Hip Surgery, Women Using Topical Estrogen Have Higher Risk Of UTIs, Study Finds - Drugs.com MedNews
THURSDAY, Oct. 22, 2026 Older women who use topical estrogen to prevent recurrent urinary tract infections might wind up with a UTI anyway after hip fracture su
www.drugs.com
October 22, 2026 at 6:17 PM
In a study of 375 women aged 50 and older, about 1 in 4 developed a urinary tract infection after hip fracture surgery. Those who had used vaginal estrogen beforehand were more likely to, though most already had recurrent UTIs. www.drugs.com/news/after-h...
From #UEGWeek2026 - The burden of disability from alcohol-related cirrhosis and heart failure is predicted to sharply increase in Europe and the USA by 2050.
Full story 👉️ buff.ly/T5cvw1A
#MedNews
Full story 👉️ buff.ly/T5cvw1A
#MedNews
Alcohol-related cirrhosis and heart failure disability increasing across Europe, USA
The burden of disability from alcohol-related cirrhosis and heart failure is predicted to sharply increase in Europe and the USA by 2050.
www.springermedicine.com
October 21, 2026 at 6:25 PM
From #UEGWeek2026 - The burden of disability from alcohol-related cirrhosis and heart failure is predicted to sharply increase in Europe and the USA by 2050.
Full story 👉️ buff.ly/T5cvw1A
#MedNews
Full story 👉️ buff.ly/T5cvw1A
#MedNews
Testosterone therapy may raise the risk of heart attack and stroke in postmenopausal women. In a study of over 6,300 women, about 4% prescribed testosterone had heart problems, versus 0.5% of those who were not. Findings are preliminary until peer-reviewed. www.drugs.com/news/testost...
Testosterone Therapy Linked To Heart Attack, Stroke Among Aging Women - Drugs.com MedNews
TUESDAY, Oct. 20, 2026 Older women might want to think twice before taking testosterone to treat their lagging libido, a new study says. Testosterone therapy ap
www.drugs.com
October 20, 2026 at 9:06 PM
Testosterone therapy may raise the risk of heart attack and stroke in postmenopausal women. In a study of over 6,300 women, about 4% prescribed testosterone had heart problems, versus 0.5% of those who were not. Findings are preliminary until peer-reviewed. www.drugs.com/news/testost...
From #EURETINA2026 - Researchers have shown a five-fold reduction in the risk for contralateral retinal detachment in patients with #SticklerSyndrome using prophylactic laser photocoagulation.
Full story 👉️ buff.ly/S8O0xYi
#MedNews
Full story 👉️ buff.ly/S8O0xYi
#MedNews
Real-world data support laser photocoagulation to reduce contralateral retinal detachment risk
Researchers have shown a five-fold reduction in the risk for contralateral retinal detachment in patients with Stickler syndrome using prophylactic laser photocoagulation.
buff.ly
October 21, 2026 at 3:15 PM
From #EURETINA2026 - Researchers have shown a five-fold reduction in the risk for contralateral retinal detachment in patients with #SticklerSyndrome using prophylactic laser photocoagulation.
Full story 👉️ buff.ly/S8O0xYi
#MedNews
Full story 👉️ buff.ly/S8O0xYi
#MedNews
From #EASD2026 - Diabetes management may be aided by #GLP1 receptor agonist use in young people with type 2 diabetes, and a very-low-carbohydrate diet in children with type 1 diabetes.
Full story 👉️ buff.ly/qI4KxNr
#PediatricDiabetes #MedNews
Full story 👉️ buff.ly/qI4KxNr
#PediatricDiabetes #MedNews
October 20, 2026 at 3:15 PM
From #EASD2026 - Diabetes management may be aided by #GLP1 receptor agonist use in young people with type 2 diabetes, and a very-low-carbohydrate diet in children with type 1 diabetes.
Full story 👉️ buff.ly/qI4KxNr
#PediatricDiabetes #MedNews
Full story 👉️ buff.ly/qI4KxNr
#PediatricDiabetes #MedNews
A study of about 3,900 women found that menopause hormone therapy may improve weight loss from GLP-1 drugs. Women on semaglutide plus hormone therapy lost about 11% of body weight at one year, versus 9.5% on semaglutide alone. Findings are preliminary. www.drugs.com/news/menopau...
Menopause Hormone Therapy Might Boost GLP-1 Weight Loss Results, Study Says - Drugs.com MedNews
WEDNESDAY, Oct. 21, 2026 Hormone therapy for menopause might actually boost the weight-loss benefits of drugs like Ozempic and Zepbound, a new study says.Middle
www.drugs.com
October 21, 2026 at 5:50 PM
A study of about 3,900 women found that menopause hormone therapy may improve weight loss from GLP-1 drugs. Women on semaglutide plus hormone therapy lost about 11% of body weight at one year, versus 9.5% on semaglutide alone. Findings are preliminary. www.drugs.com/news/menopau...